The Annexin A2 Pathway in Proliferative Vitreoretinopathy: A New Therapeutic Target

Abstract

Proliferative vitreoretinopathy (PVR) occurs in patients with penetrating ocular injury, of which there are more than 200,000worldwide per year among both military and civilian personnel. It is a major challenge in ophthalmology and retinal surgery. Experts agree that PVR results from proliferation and migration of retinal pigment epithelial (RPE) cells, through a retinal wound and over the vitreal surface of the retina. There, RPE cells secrete collagen and other matrix proteins that form an epiretinal scar-like membrane that exerts tractional forces on the retina, often leading to retinal detachment and loss of vision. At present there are no reliable means of treating or preventing PVR. This program would develop a potential new biologic therapy, based on targeting the annexin A2 cell surface fibrinolytic system and stimulators of the system (macrophage inflammatory protein (MIP) 1-alpha and MIF 1-beta, for early point-of-care prevention of PVR.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2022
Accession Number
AD1194704

Entities

People

  • Katherine A Hajjar

Organizations

  • Cornell University

Tags

DTIC Thesaurus Topics

  • Antibodies
  • Biological Pigments
  • Biomedical Research
  • Cell Movement
  • Cells
  • Civilian Personnel
  • Epithelial Cells
  • Eye Injuries
  • Histology
  • Macrophages
  • Maryland
  • Medical Personnel
  • Ophthalmology
  • Retinal Diseases
  • Standards
  • Students
  • Surface Plasmon Resonance
  • Surface Plasmons
  • Targets
  • Tissues

Fields of Study

  • Medicine

Readers

  • Materials Science.
  • Oncology (Cancer Research).
  • Vision Science/Vision Psychology/Cognitive Neuroscience.